Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Operating Expenses (2016 - 2026)

Champions Oncology has reported Operating Expenses over the past 17 years, most recently at $16.8 million for Q1 2026.

  • Quarterly results put Operating Expenses at $16.8 million for Q1 2026, up 34.25% from a year ago — trailing twelve months through Jan 2026 was $60.6 million (up 15.81% YoY), and the annual figure for FY2025 was $52.4 million, down 8.9%.
  • Operating Expenses for Q1 2026 was $16.8 million at Champions Oncology, up from $14.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for CSBR hit a ceiling of $16.8 million in Q1 2026 and a floor of $12.4 million in Q1 2022.
  • Median Operating Expenses over the past 5 years was $14.3 million (2022), compared with a mean of $14.2 million.
  • Biggest five-year swings in Operating Expenses: decreased 15.75% in 2024 and later soared 34.25% in 2026.
  • Champions Oncology's Operating Expenses stood at $14.3 million in 2022, then decreased by 5.23% to $13.5 million in 2023, then fell by 5.7% to $12.8 million in 2024, then grew by 16.41% to $14.8 million in 2025, then increased by 13.37% to $16.8 million in 2026.
  • The last three reported values for Operating Expenses were $16.8 million (Q1 2026), $14.8 million (Q4 2025), and $14.5 million (Q3 2025) per Business Quant data.